Adiponectin protects against lung ischemia-reperfusion injury in rats with type 2 diabetes mellitus

Li,Di; Song,Lin‑Lin; Wang,Juan; Meng,Chao; Cui,Xiao‑Guang

doi:10.3892/mmr.2018.8748

Adiponectin protects against lung ischemia-reperfusion injury in rats with type 2 diabetes mellitus

Authors:
- Di Li
- Lin‑Lin Song
- Juan Wang
- Chao Meng
- Xiao‑Guang Cui
View Affiliations

Affiliations: Department of Anesthesiology, The Heilongjiang Province Key Laboratory of Research on Anesthesiology and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: March 14, 2018 https://doi.org/10.3892/mmr.2018.8748
Pages: 7191-7201
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adiponectin (APN) has been associated with the pathogenesis of acute brain, liver and heart injury. However, the role of APN in lung ischemia-reperfusion injury (LIRI) in diabetes mellitus remains unclear. To investigate this, the present study evaluated the effects of APN on lung dysfunction and pathological alterations in rats with type 2 diabetes mellitus via lung ischemia/reperfusion (I/R). The lung‑protective effects of APN globular domain (gAPN) in rats with type 2 diabetes mellitus were also investigated by measuring the oxygenation index, inflammatory cytokines, lung edema, histopathology, oxidative stress, apoptosis and the protein expression levels of phosphorylated 5'adenosine monophosphate‑activated protein kinase (p‑AMPK), endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS). The results of the present study demonstrated that the diabetes mellitus rats + I/R (DIR) group exhibited greater concentrations of tumor necrosis factor‑α and interleukin‑6, and increases in the wet‑weight to dry‑weight ratio, lung injury score, oxidative stress and cellular apoptosis. These effects were accompanied by lower pulmonary oxygenation compared with the normal rat + I/R (NIR) group (P<0.05). Additionally, all of these alterations were attenuated in the NIR + gAPN and DIR + gAPN groups compared with in the NIR and DIR groups, respectively. In the DIR group, the expression levels of p‑AMPK/AMPK and eNOS were significantly downregulated, and the levels of iNOS were upregulated, compared with those of the NIR group. Treatment with APN activated AMPK, increased eNOS expression and attenuated iNOS expression. The results of the present study demonstrated that APN exerted protective effects against LIRI via its anti‑inflammatory, antioxidative stress and anti‑apoptotic activities. These protective effects of APN were eliminated in rats with type 2 diabetes mellitus, in which LIRI was exacerbated. The present study indicated that APN may be a potential therapeutic agent for LIRI in type 2 diabetes mellitus.

View Figures

View References

1	Fernandez LG, Sharma AK, LaPar DJ, Kron IL and Laubach VE: Adenosine A1 receptor activation attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 145:1654–1659. 2013. View Article : Google Scholar : PubMed/NCBI
2	den Hengst WA, Gielis JF, Lin JY, Van Schil PE, De Windt LJ and Moens AL: Lung ischemia-reperfusion injury: A molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol. 299:H1283–H1299. 2010. View Article : Google Scholar : PubMed/NCBI
3	Chen GM, Hu N, Liu L, Xie SS, Wang P, Li J, Xie L, Wang GJ and Liu XD: Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica. 41:494–500. 2011. View Article : Google Scholar : PubMed/NCBI
4	Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ and Ma XL: Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 115:1408–1416. 2007. View Article : Google Scholar : PubMed/NCBI
5	Yi W, Sun Y, Gao E, Wei X, Lau WB, Zheng Q, Wang Y, Yuan Y, Wang X, Tao L, et al: Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms. Antioxid Redox Signal. 15:1779–1788. 2011. View Article : Google Scholar : PubMed/NCBI
6	Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J and Whincup PH: Adiponectin and coronary heart disease: A prospective study and meta-analysis. Circulation. 114:623–629. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kahn BB, Alquier T, Carling D and Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15–25. 2005. View Article : Google Scholar : PubMed/NCBI
8	Whitehead JP, Richards AA, Hickman IJ, Macdonald GA and Prins JB: Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 8:264–280. 2006. View Article : Google Scholar : PubMed/NCBI
9	Thakur V, Pritchard MT, McMullen MR and Nagy LE: Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 290:G998–G1007. 2006. View Article : Google Scholar : PubMed/NCBI
10	Chen B, Liao WQ, Xu N, Xu H, Wen JY, Yu CA, Liu XY, Li CL, Zhao SM and Campbell W: Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res. 1273:129–137. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kola B, Boscaro M, Rutter GA, Grossman AB and Korbonits M: Expanding role of AMPK in endocrinology. Trends Endocrinol Metab. 17:205–215. 2006. View Article : Google Scholar : PubMed/NCBI
12	Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L and Andreelli F: Activation of AMP-activated protein kinase in the liver: A new strategy for the management of metabolic hepatic disorders. J Physiol. 574:41–53. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T and Walsh K: Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem. 279:1304–1309. 2004. View Article : Google Scholar : PubMed/NCBI
14	Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, et al: Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation. 100:2473–2476. 1999. View Article : Google Scholar : PubMed/NCBI
15	Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, et al: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 23:85–89. 2003. View Article : Google Scholar : PubMed/NCBI
16	Bouhali T, Brisson D, St-Pierre J, Tremblay G, Perron P, Laprise C, Vohl MC, Vissers MN, Hutten BA, Després JP, et al: Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. Atherosclerosis. 196:262–269. 2008. View Article : Google Scholar : PubMed/NCBI
17	Laubach VE and Kron IL: Pulmonary inflammation after lung transplantation. Surgery. 146:1–4. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zheng H, Wu J, Jin Z and Yan LJ: Potential biochemical mechanisms of lung injury in diabetes. Aging Dis. 8:7–16. 2017. View Article : Google Scholar : PubMed/NCBI
19	Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al: Prevalence of diabetes among men and women in China. N Engl J Med. 362:1090–1101. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hackman KL, Snell GI and Bach LA: An unexpectedly high prevalence of undiagnosed diabetes in patients awaiting lung transplantation. J Heart Lung Transplant. 32:86–91. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ambur V, Taghavi S, Jayarajan S, Kadakia S, Zhao H, Gomez-Abraham J and Toyoda Y: The impact of lungs from diabetic donors on lung transplant recipients†. Eur J Cardiothorac Surg. 51:285–290. 2017.PubMed/NCBI
22	Kuitert LM: The lung in diabetes-yet another target organ? Chron Respir Dis. 5:67–68. 2008. View Article : Google Scholar : PubMed/NCBI
23	Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, Incalzi RA and Ghirlanda G: The diabetic lung-a new target organ? Rev Diabet Stud. 9:23–35. 2012. View Article : Google Scholar : PubMed/NCBI
24	Williams JG, Morris AI, Hayter RC and Ogilvie CM: Respiratory responses of diabetics to hypoxia, hypercapnia, and exercise. Thorax. 39:529–534. 1984. View Article : Google Scholar : PubMed/NCBI
25	Dennis RJ, Maldonado D, Rojas MX, Aschner P, Rondón M, Charry L and Casas A: Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: A cross-sectional study. BMC Pulm Med. 10:382010. View Article : Google Scholar : PubMed/NCBI
26	Engström G, Hedblad B, Nilsson P, Wollmer P, Berglund G and Janzon L: Lung function, insulin resistance and incidence of cardiovascular disease: A longitudinal cohort study. J Intern Med. 253:574–581. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kim CH, Kim HK, Kim EH, Bae SJ, Jung YJ, Choi J and Park JY: Association of restrictive ventilatory dysfunction with the development of prediabetes and type 2 diabetes in Koreans. Acta Diabetol. 52:357–363. 2015. View Article : Google Scholar : PubMed/NCBI
28	Chiang CH, Hsu K, Yan HC, Harn HJ and Chang DM: PGE1, dexamethasone, U-74389G, or Bt2-cAMP as an additive to promote protection by UW solution in I/R injury. J Appl Physiol (1985). 83:583–590. 1997. View Article : Google Scholar : PubMed/NCBI
29	Pirat A, Zeyneloglu P, Aldemir D, Yücel M, Ozen O, Candan S and Arslan G: Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg. 102:225–232. 2006. View Article : Google Scholar : PubMed/NCBI
30	Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K and Tobe K: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116:784–792. 2006. View Article : Google Scholar
31	Wang Y, Xu LY, Lam KS, Lu G, Cooper GJ and Xu A: Proteomic characterization of human serum proteins associated with the fat-derived hormone adiponectin. Proteomics. 6:3862–3870. 2006. View Article : Google Scholar : PubMed/NCBI
32	Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE and Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 98:pp. 2005–2010. 2001; View Article : Google Scholar : PubMed/NCBI
33	Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:941–946. 2001. View Article : Google Scholar : PubMed/NCBI
34	Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, et al: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 43:1318–1323. 2004. View Article : Google Scholar : PubMed/NCBI
35	Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 8:1288–1295. 2002. View Article : Google Scholar : PubMed/NCBI
36	Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N and Walsh K: Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 11:1096–1103. 2005. View Article : Google Scholar : PubMed/NCBI
37	Hardie DG, Carling D and Carlson M: The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 67:821–855. 1998. View Article : Google Scholar : PubMed/NCBI
38	Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T and Walsh K: Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem. 279:28670–28674. 2004. View Article : Google Scholar : PubMed/NCBI
39	Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T and Matsuzawa Y: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 94:e27–e31. 2004. View Article : Google Scholar : PubMed/NCBI
40	Chen H, Montagnani M, Funahashi T, Shimomura I and Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 278:45021–45026. 2003. View Article : Google Scholar : PubMed/NCBI
41	Konter JM, Parker JL, Baez E, Li SZ, Ranscht B, Denzel M, Little FF, Nakamura K, Ouchi N, Fine A, et al: Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J Immunol. 188:854–863. 2012. View Article : Google Scholar : PubMed/NCBI
42	He Y, Zou L, Zhou Y, Hu H, Yao R, Jiang Y, Lau WB, Yuan T, Huang W, Zeng Z and Cao Y: Adiponectin ameliorates the apoptotic effects of paraquat on alveolar type cells via improvements in mitochondrial function. Mol Med Rep. 14:746–752. 2016. View Article : Google Scholar : PubMed/NCBI
43	Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y and Abraham E: Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 295:L497–L504. 2008. View Article : Google Scholar : PubMed/NCBI
44	Becker J, Delayre-Orthez C, Frossard N and Pons F: Regulation of inflammation by PPARs: A future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol. 20:429–447. 2006. View Article : Google Scholar : PubMed/NCBI
45	Alba G, El Bekay R, Alvarez-Maqueda M, Chacón P, Vega A, Monteseirín J, Santa María C, Pintado E, Bedoya FJ, Bartrons R and Sobrino F: Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils. FEBS Lett. 573:219–225. 2004. View Article : Google Scholar : PubMed/NCBI
46	Song P and Zou MH: Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems. Free Radic Biol Med. 52:1607–1619. 2012. View Article : Google Scholar : PubMed/NCBI
47	Berg AH, Combs TP, Du X, Brownlee M and Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 7:947–953. 2001. View Article : Google Scholar : PubMed/NCBI
48	Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y and Nagai R: Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother. 62:46–52. 2008. View Article : Google Scholar : PubMed/NCBI